Solid Biosciences LLC - Asset Resilience Ratio
Solid Biosciences LLC (SLDB) has an Asset Resilience Ratio of 63.81% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Solid Biosciences LLC for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Solid Biosciences LLC's Asset Resilience Ratio has changed over time. See SLDB net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Solid Biosciences LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Solid Biosciences LLC stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $174.78 Million | 63.81% |
| Total Liquid Assets | $174.78 Million | 63.81% |
Asset Resilience Insights
- Very High Liquidity: Solid Biosciences LLC maintains exceptional liquid asset reserves at 63.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Solid Biosciences LLC Industry Peers by Asset Resilience Ratio
Compare Solid Biosciences LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Solid Biosciences LLC (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Solid Biosciences LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.41% | $68.69 Million | $188.66 Million | +6.32pp |
| 2023-12-31 | 30.09% | $49.62 Million | $164.94 Million | +7.67pp |
| 2022-12-31 | 22.42% | $58.34 Million | $260.25 Million | -15.73pp |
| 2021-12-31 | 38.15% | $88.64 Million | $232.38 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $171.17 Million | -- |
| 2019-12-31 | 7.23% | $7.48 Million | $103.47 Million | -18.63pp |
| 2018-12-31 | 25.86% | $36.10 Million | $139.60 Million | +3.53pp |
| 2017-12-31 | 22.33% | $17.01 Million | $76.19 Million | -51.45pp |
| 2016-12-31 | 73.78% | $29.98 Million | $40.64 Million | +25.67pp |
| 2015-12-31 | 48.10% | $26.79 Million | $55.70 Million | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular ta… Read more